Overall survival
| Variables . | EUROCORD (N = 496) . | JSTCT (N = 1150) . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Year of transplant, continuous variable | 0.99 | (0.95-1.03) | .648 | 0.96 | (0.94-0.98) | <.001 |
| Age∗ (<50 or ≥50) | ||||||
| 18-49 | 1.00 | Reference | 1.00 | Reference | ||
| 50-70 | 1.28 | (0.98-1.67) | .074 | 1.48 | (1.26-1.74) | <.001 |
| rDRI | ||||||
| Low | 1.00 | Reference | 1.00 | Reference | ||
| Intermediate | 1.19 | (0.89-1.58) | .239 | 1.36 | (0.97-1.91) | .071 |
| High or very high | 1.87 | (1.31-2.69) | .001 | 2.34 | (1.69-3.25) | <.001 |
| Conditioning | ||||||
| TBI-RIC | 1.00 | Reference | 1.00 | Reference | ||
| TBI-MAC | 1.15 | (0.71-1.86) | .580 | 1.05 | (0.85-1.28) | .663 |
| Non–TBI-RIC | 1.93 | (1.38-2.70) | <.001 | 1.71 | (1.40-2.10) | <.001 |
| Non–TBI-MAC | 1.90 | (1.25-2.90) | .003 | 1.50 | (1.12-2.03) | .007 |
| GVHD prophylaxis | ||||||
| CI + MMF | 1.00 | Reference | 1.00 | Reference | ||
| CI + MTX | NA | NA | NA | 1.46 | (1.20-1.78) | <.001 |
| CI + steroid | 1.18 | (0.78-1.79) | .444 | NA | NA | NA |
| Others | 1.32 | (0.92-1.89) | .128 | 1.68 | (1.35-2.08) | <.001 |
| Number of HLA-MM | ||||||
| 0-1 | 1.00 | Reference | 1.00 | Reference | ||
| 2- | 1.52 | (1.12-2.07) | .007 | 1.18 | (0.97-1.44) | .107 |
| Variables . | EUROCORD (N = 496) . | JSTCT (N = 1150) . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Year of transplant, continuous variable | 0.99 | (0.95-1.03) | .648 | 0.96 | (0.94-0.98) | <.001 |
| Age∗ (<50 or ≥50) | ||||||
| 18-49 | 1.00 | Reference | 1.00 | Reference | ||
| 50-70 | 1.28 | (0.98-1.67) | .074 | 1.48 | (1.26-1.74) | <.001 |
| rDRI | ||||||
| Low | 1.00 | Reference | 1.00 | Reference | ||
| Intermediate | 1.19 | (0.89-1.58) | .239 | 1.36 | (0.97-1.91) | .071 |
| High or very high | 1.87 | (1.31-2.69) | .001 | 2.34 | (1.69-3.25) | <.001 |
| Conditioning | ||||||
| TBI-RIC | 1.00 | Reference | 1.00 | Reference | ||
| TBI-MAC | 1.15 | (0.71-1.86) | .580 | 1.05 | (0.85-1.28) | .663 |
| Non–TBI-RIC | 1.93 | (1.38-2.70) | <.001 | 1.71 | (1.40-2.10) | <.001 |
| Non–TBI-MAC | 1.90 | (1.25-2.90) | .003 | 1.50 | (1.12-2.03) | .007 |
| GVHD prophylaxis | ||||||
| CI + MMF | 1.00 | Reference | 1.00 | Reference | ||
| CI + MTX | NA | NA | NA | 1.46 | (1.20-1.78) | <.001 |
| CI + steroid | 1.18 | (0.78-1.79) | .444 | NA | NA | NA |
| Others | 1.32 | (0.92-1.89) | .128 | 1.68 | (1.35-2.08) | <.001 |
| Number of HLA-MM | ||||||
| 0-1 | 1.00 | Reference | 1.00 | Reference | ||
| 2- | 1.52 | (1.12-2.07) | .007 | 1.18 | (0.97-1.44) | .107 |
95% CI, 95% confidence interval; HLA-MM, HLA mismatches; NA, not available.
Results of the analysis statistically significant (with P < .05) are highlighted in bold.
Indicates patients' age at CBT.